MX343366B - Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica. - Google Patents

Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica.

Info

Publication number
MX343366B
MX343366B MX2013003330A MX2013003330A MX343366B MX 343366 B MX343366 B MX 343366B MX 2013003330 A MX2013003330 A MX 2013003330A MX 2013003330 A MX2013003330 A MX 2013003330A MX 343366 B MX343366 B MX 343366B
Authority
MX
Mexico
Prior art keywords
peptides
methods
neurological disease
treating neurological
src
Prior art date
Application number
MX2013003330A
Other languages
English (en)
Other versions
MX2013003330A (es
Inventor
Michael Tymianski
Rongwen Li
Jonathan David Garman
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Publication of MX2013003330A publication Critical patent/MX2013003330A/es
Publication of MX343366B publication Critical patent/MX343366B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
    • C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a la identificación de una región central de ND2 responsable por interactuar con Src dentro de los residuos 289-321 de ND2 y más en particular los residuos 310-321 de ND2. Péptidos que incluyen, que se traslapan o desde dentro de esta región pueden ser usados para inhibir la interacción de ND2 con Src. La inhibición de esta interacción es útil para el tratamiento o profilaxis de enfermedades y alteraciones neurológicas, dolor y cáncer.
MX2013003330A 2010-09-28 2011-09-28 Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica. MX343366B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38743910P 2010-09-28 2010-09-28
PCT/US2011/053764 WO2012050921A2 (en) 2010-09-28 2011-09-28 Nd2 peptides and methods of treating neurological disease

Publications (2)

Publication Number Publication Date
MX2013003330A MX2013003330A (es) 2013-09-26
MX343366B true MX343366B (es) 2016-11-01

Family

ID=45938878

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003330A MX343366B (es) 2010-09-28 2011-09-28 Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica.

Country Status (15)

Country Link
US (1) US9073976B2 (es)
EP (1) EP2621945B1 (es)
JP (1) JP6073230B2 (es)
KR (1) KR101893473B1 (es)
CN (1) CN103282379B (es)
AU (1) AU2011314074B2 (es)
BR (1) BR112013007557A2 (es)
CA (1) CA2812948C (es)
DK (1) DK2621945T3 (es)
IL (1) IL225464B (es)
MX (1) MX343366B (es)
RU (1) RU2607033C2 (es)
SG (1) SG189104A1 (es)
UA (1) UA114592C2 (es)
WO (1) WO2012050921A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015265487B2 (en) * 2014-05-28 2020-08-13 Nono Inc. Chloride salt of TAT-NR2B9c
EP3420087B1 (en) * 2016-02-23 2021-09-01 The Regents of The University of Colorado, A Body Corporate Peptide-based methods for treating neurological injury
US11229675B2 (en) * 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CN112679595B (zh) * 2020-04-10 2022-11-01 南京市儿童医院 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300985A1 (en) * 1997-08-12 1999-02-18 Bristol-Myers Squibb Company Kcnq potassium channels and methods of modulating same
AU3885300A (en) 1999-03-19 2000-10-09 Human Genome Sciences, Inc. 50 human secreted proteins
PT1399483E (pt) * 2001-01-05 2010-07-20 Pfizer Anticorpos contra o receptor do factor i de crescimento tipo insulina
US7304071B2 (en) * 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US20060030534A1 (en) * 2002-09-04 2006-02-09 Gabriele Dorn Treatment of neurological disorders by dsrna administration
US7425540B2 (en) 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
US8003609B2 (en) * 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
AU2006261342B2 (en) * 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels

Also Published As

Publication number Publication date
US9073976B2 (en) 2015-07-07
AU2011314074B2 (en) 2015-11-12
IL225464A0 (en) 2013-06-27
AU2011314074A1 (en) 2013-05-09
KR20140048070A (ko) 2014-04-23
RU2013119830A (ru) 2014-11-10
CN103282379B (zh) 2016-01-06
IL225464B (en) 2018-03-29
CA2812948A1 (en) 2012-04-19
DK2621945T3 (en) 2018-05-22
CA2812948C (en) 2019-01-22
EP2621945B1 (en) 2018-04-11
MX2013003330A (es) 2013-09-26
US20140274906A1 (en) 2014-09-18
UA114592C2 (uk) 2017-07-10
CN103282379A (zh) 2013-09-04
BR112013007557A2 (pt) 2021-05-11
JP6073230B2 (ja) 2017-02-01
RU2607033C2 (ru) 2017-01-10
EP2621945A4 (en) 2014-05-07
WO2012050921A3 (en) 2012-07-05
JP2014505655A (ja) 2014-03-06
KR101893473B1 (ko) 2018-08-30
WO2012050921A2 (en) 2012-04-19
SG189104A1 (en) 2013-05-31
EP2621945A2 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
MY161656A (en) Therapeutic use of diaminophenothiazines
AU2011328009A8 (en) Compounds and methods for treating pain
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
WO2013061161A3 (en) New combination therapies for treating neurological disorders
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
IN2014DN00288A (es)
IN2014DN00286A (es)
IN2014MN00093A (es)
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
IN2014MN01378A (es)
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
IN2015DN00450A (es)
WO2012015758A3 (en) Methods of treating pain
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MX2013003076A (es) Terapeuticos contra cancer de mama.
MX2009010407A (es) Derivados fluorados de deferiprona.
IN2012DN05186A (es)
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
MX343366B (es) Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.

Legal Events

Date Code Title Description
FG Grant or registration